Meridian Bioscience

Meridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Meridian Bioscience is an integrated life science company. The Company is engaged in developing, manufacturing, selling, and distributing clinical diagnostic test kits, for certain gastrointestinal, viral, respiratory, and parasitic infectious diseases; the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/ quantitative polymerase chain reaction (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers, and the contract development and manufacture of proteins and other biologicals under cyclic guanosine monophosphate (cGMP) conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. The Company operates in three segments: U.S. Diagnostics, European Diagnostics, and Life Science.

Meridian Bioscience Inc VIVO has posted Q1 FY22 sales of $88.2 million, down 4.9% Y/Y, sharply beating the consensus of $70.29 million. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Why Meridian Bioscience's Shares Are Rising Today?

Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 40% and 19.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Meridian Bioscience (VIVO) Q1 Earnings and Revenues Surpass Estimates

CINCINNATI, Feb. 4, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2021. First Quarter Fiscal 2022 Highlights (Comparison to First Quarter Fiscal 2021): Consolidated net revenues of $88.3 million, second best in company history with both segments ahead of expectations Life Science segment delivered net revenues of $55.1 million Diagnostics segment net revenues increased 10% year-over-year to $33.2 million Launched first Lyo-Ready™ sample-specific master mix for saliva-based assays Received FDA 510(k) clearance for Curian® Campy assay and Emergency Use Authorization for Revogene® SARS-CoV-2 assay Jack Kenny, Chief Executive Officer, commented, "While disappointed that we are fighting yet another wave of COVID-19 infections across the globe, I am pleased to report that Meridian delivered an outstanding quarter.

MERIDIAN BIOSCIENCE REPORTS SECOND BEST QUARTER IN COMPANY HISTORY

CINCINNATI, Jan. 31, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has been awarded additional funding in the amount of $2.5M by the National Institute of Health (NIH) Rapid Acceleration of Diagnostics (RADx®) initiative. This award expands the scope of the original $5.5M award to help support the research, development, and increased production of the company's Revogene® molecular viral respiratory diagnostic testing panel.

Meridian Bioscience Receives Additional NIH Award to Support the Rapid Development of the Revogene® Molecular Viral Respiratory Testing Panel

Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Meridian Bioscience (VIVO) Q1 Earnings Expected to Decline

CINCINNATI , Jan. 28, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of two new master mixes that detect DNA and RNA in crude saliva samples.  These two new mixes, Lyo-Ready™ Direct DNA qPCR Saliva Mix and Lyo-Ready™ Direct RNA/DNA qPCR Saliva Mix can be used in liquid format or lyophilized.

Meridian Bioscience Launches Lyo-Ready™ qPCR Saliva-Specific Master Mixes for DNA & RNA Direct Detection

CINCINNATI, Jan. 27, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that John C. McIlwraith has been elected as Chairman of the Meridian Board of Directors, effective January 26, 2022.

Meridian Bioscience Elects John C. McIlwraith New Chairman of the Board

CINCINNATI, Jan. 10, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, will report first quarter 2022 financial results Friday, February 4, 2022. Jack Kenny, Chief Executive Officer, will host a conference call beginning at 10:00 a.m.

Meridian Bioscience to Hold First Quarter 2022 Financial Results Conference Call on February 4, 2022

CINCINNATI, Jan. 5, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that the Curian® Campy assay has received U.S. Food and Drug Administration (FDA) clearance.  The Curian Campy assay is a rapid, qualitative fluorescent immunoassay for the detection of a Campylobacter-specific antigen including C.

Meridian Bioscience Receives FDA-Clearance for the Curian® Campy Assay

CINCINNATI, Jan. 4, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of diagnostic testing solutions and life science raw materials, announced today its participation in the 2022 H. C. Wainwright Bioconnect Virtual Conference.

Meridian Bioscience to Participate in the 2022 H. C. Wainwright Bioconnect Virtual Conference

Amphastar Pharma

Johnson Outdoors

When screening the market for bargain opportunities, investors may want to look for stocks whose trailing 12-month and forward price-earnings to growth (PEG) ratios are at or below 1.5 as of Dec. 13, which is the S&P 500's historical average PEG ratio.

3 Stocks With Low PEG Ratios

CINCINNATI, Dec. 2, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Bryan Baldasare, Executive Vice President, Chief Financial Officer, and Secretary, will retire from Meridian effective December 31, 2021.  The Company is engaging an executive search firm in the recruitment of a new chief financial officer.

Meridian Bioscience Announces Retirement of CFO Bryan Baldasare

CINCINNATI, Nov. 24, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that David Phillips, Chairman of the Board of Directors, will retire from the Board of Directors and not seek re-election when his term ends in January 2022.  The Board of Directors will elect a new chair when Mr.

Meridian Bioscience Announces Retirement of Chairman David Phillips

CINCINNATI, Nov. 17, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of its Air-Dryable™ LAMP Mix and Air-Dryable™ RT-LAMP 1-Step Mix. These ground-breaking molecular master mixes are specifically designed for fast isothermal amplification of nucleic acid sequences, not only to facilitate the development of point-of-care ambient temperature-stable assays, but also to accelerate diagnosis.

Meridian Launches Two New Air-Dryable™ Mixes for Isothermal Amplification, Powering Shortest Time-to-results in Point-of-care Testing

Meridian Bioscience, Inc. (VIVO) CEO Jack Kenny on Q4 2021 Earnings Conference Call - Earnings Call Transcript

Meridian Bioscience Inc (NASDAQ: VIVO) posted Q4 sales of $76.2 million, up 19% Y/Y, beating the consensus of $68.40 million. Diagnostics segment net revenues increased 15% Y/Y to $34.3 million, led by a 22% increase in molecular products sales, and non-molecular assay products sales increased 14%, despite the impact of the LeadCare product recall.

Meridian Bioscience's Q4 Earnings Beat Expectations

CINCINNATI, Nov. 12, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2021. Fourth Quarter 2021 Highlights (Comparison to Fourth Quarter Fiscal 2020): Consolidated net revenues of $76.2 million, up 19% year-over-year Life Science segment delivered net revenues of $41.9 million, up 22% year-over-year Diagnostics segment net revenues increased 15% year-over-year to $34.3 million Launched Air-Dryable™ sample specific master mixes for stool, blood and urine and Air-Dryable™ LAMP Mix for isothermal amplification Received U.S. design patent for Revogene® PIE (Fluidic Centripetal Device) Launched new environmentally friendly, REACH compliant, enzymes Closed $20 million acquisition of the BreathTek® Urea Breath Test for H.

Meridian Bioscience Reports Strong Fourth Quarter And Record Full-Year Fiscal 2021 Operating Results And Provides Fiscal 2022 Guidance

CINCINNATI, Nov. 10, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that their Revogene® SARS-CoV-2 assay was granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA).  Meridian expects to begin shipping this product before the end of its fiscal first quarter, ending December 31, 2021.

Meridian Bioscience Receives FDA Emergency Use Authorization for Revogene® SARS-CoV-2 Molecular Assay

Meridian Bioscience (VIVO) Earnings Expected to Grow: Should You Buy?

CINCINNATI, Oct. 27, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of two innovative Air-Dryable™ qPCR Mixes that enable direct detection of DNA or RNA/DNA from urine samples. Meridian developed these unique master mixes specifically to overcome the adverse effect of inhibitors present in crude urine samples that can affect the sensitivity of a molecular assay.

Meridian Launches Innovative Air-Dryable™ qPCR Mixes Enabling Direct Detection of DNA or RNA from Urine Samples

CINCINNATI, Oct. 14, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, will report fourth quarter and full year 2021 financial results Friday, November 12, 2021. Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will host a conference call beginning at 10:00 a.m.

Meridian Bioscience to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Call on November 12, 2021

CINCINNATI, Oct. 7, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of its new Air-Dryable™ Direct RNA/DNA qPCR Blood Mix. Meridian designed this innovative master mix to develop room-temperature stable molecular diagnostic assays that directly amplify RNA from crude whole blood, serum, or plasma.

Meridian Launches New Air-Dryable™ qPCR Mix Enabling Direct Detection of RNA from Whole Blood Samples

CINCINNATI, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the addition of two new Air-Dryable™ Master Mixes with the launch of its Air-Dryable™ Direct DNA qPCR Stool and Air-Dryable™ Direct RNA/DNA qPCR Stool Mixes. These innovative master mixes are designed to develop room-temperature stable molecular diagnostic assays that directly target nucleic acid sequences from crude stool material.

Meridian Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detection of DNA or RNA from Stool Samples

CINCINNATI, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of its new Air-Dryable™ Direct DNA qPCR Saliva and Air-Dryable™ Direct RNA/DNA qPCR Saliva Mixes, which are designed for incorporation in room-temperature stable molecular assays, directly targeting nucleic acid sequence from saliva and sputum.

Meridian Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detection of DNA or RNA from Saliva Samples

Meridian Bioscience Inc's (NASDAQ: VIVO) subsidiary Magellan Diagnostics Inc has expanded the Class I recall of its LeadCare Test Kits used to detect lead in whole blood. Magellan provides two controls in the test kits designed to mimic blood and are spiked with lead to specific target values with an associated acceptable range.

News for Meridian Bioscience Stock (VIVO)